Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,099 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bioavailability Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

NCT04898101
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, Microtracer [14C]ACP-196
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute Glycine Pharmacodynamic Study

NCT01610011
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Glycine administration
Dietary Supplement
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

NCT02310750
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
PF-06700841 oral solution/suspension, Placebo, PF-06700841 tablet
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354

NCT00638989
View directory record Official record
Conditions
Asthma, Healthy
Interventions
CAT-354 150 mg (intravenous), CAT-354 150 mg (subcutaneous), CAT-354 300 mg (subcutaneous)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers

NCT05690932
View directory record Official record
Conditions
Formulation Bridging, Food Effect
Interventions
PBI-200 Tablet, PBI-200 Capsule, PBI-200 Suspension
Drug
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 27, 2026, 5:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Objective of This Study Was to Compare and Quantify the Bioavailability of Citrulline Byproducts in Blood Samples and in Urine Samples After a Single Dose of the Assigned Dietary Supplement. The Treatment Arms Containing the Following Molecules: Citrulline HCL and L-Citrulline,

NCT06977854
View directory record Official record
Conditions
Bioavailability and AUC
Interventions
Removal from study. In case of adverse event, subject treated for the AE., removal from study
Other
Lead sponsor
Vireo Systems, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

To Evaluate the Bioavailability of a Tablet of AZD1656

NCT00817505
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2009 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Furosemide 80mg Tablets Under Fasting Conditions

NCT00778180
View directory record Official record
Conditions
Healthy
Interventions
furosemide 80 mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Finasteride 5 mg Tablets, Non-fasting

NCT00835796
View directory record Official record
Conditions
Healthy
Interventions
Finasteride 5 mg tablets, PROSCAR® 5mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

NCT01152346
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Azacitidine for Injection, Vidaza®
Drug
Lead sponsor
Bioniche Pharma USA LLC
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Anaheim, California • Corona, California • Fresno, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of Pepper Carotenoids in Humans

NCT00636350
View directory record Official record
Conditions
Healthy
Interventions
Pepper
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
40 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY4065967 in Healthy Participants

NCT07607483
View directory record Official record
Conditions
Healthy
Interventions
LY4065967 Tablet, LY4065967 Formulated Capsule, LY4065967 Capsule
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

NCT07316608
View directory record Official record
Conditions
Healthy Participants
Interventions
Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2, Laroprovstat Dose X STP, Rosuvastatin Dose 1 STP, Rosuvastatin Dose 2 STP
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 27, 2026, 5:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Kaempferol Absorption and Pharmacokinetics Evaluation

NCT07322406
View directory record Official record
Conditions
No Disease, Mitochondria Health, Longevity, Pharmacokinetics and Biological Absorption of Kaempferol in Healthy Adult, Healthy Volunteers
Interventions
Kaempferol
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
New York, New York • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions

NCT01372358
View directory record Official record
Conditions
Fed
Interventions
CIPRO®XR
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Loperamide Hydrochloride 2 mg and Simethicone 125 mg Tablet Under Fasting Conditions

NCT00778115
View directory record Official record
Conditions
Healthy
Interventions
Loperamide HCl 2 mg and simethicone 125 mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

NCT02034591
View directory record Official record
Conditions
Healthy Subjects
Interventions
Apixaban, Boost Plus
Drug · Dietary Supplement
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet

NCT03362411
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986205
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects

NCT07043634
View directory record Official record
Conditions
Bioavailability Heathy Volunteers
Interventions
FDC (24 mg ER torsemide and 30 mg Spironolactone) without food, FDC (24 mg ER torsemide and 30 mg Spironolactone) with food
Combination Product
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.

NCT00840216
View directory record Official record
Conditions
Healthy
Interventions
Clarithromycin ER 500 mg tablets, BIAXIN® XL 500 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 27, 2026, 5:23 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Malarone Pharmacokinetics Under Simulated Physiologic Stressors of Deployment

NCT03991208
View directory record Official record
Conditions
Exercise, Pharmacokinetics
Interventions
Malarone
Drug
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 44 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting

NCT00834587
View directory record Official record
Conditions
Healthy
Interventions
5 mg/500 mg METAGLIP™ Tablets, 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

NCT04903093
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Abrocitinib tablet, Abrocitinib Suspension F1, Abrocitinib Suspension F2, Abrocitinib Suspension F3, Abrocitinib Suspension F4, Abrocitinib Suspension F5, Abrocitinib Suspension F6, Famotidine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 27, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)

NCT02443740
View directory record Official record
Conditions
Healthy
Interventions
BIIB118
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 27, 2026, 5:23 AM EDT